ClinicalTrials.gg
Not yet recruitingNCT07532473REMAKEUpdated Sep 15, 2026

REal World MAIA UK OutcomEs

An observational study in Myeloma, sponsored by The Royal Wolverhampton Hospitals NHS Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by The Royal Wolverhampton Hospitals NHS Trust · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom — 5 open to participants now, 6 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United Kingdom.

Started
2026
with 1 other
Observational
6 of 39
2 open now
Registered
38th of 39
by date

Among the 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 38th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

5 of the 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Neoplasms, Plasma Cell with a site in United Kingdom, or all of them as a file.
02

Study summary

This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.

Read the detailed description

Triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) for transplant ineligible (TIE) untreated myeloma patients (MAIA) was reported in 2019. NICE approved this in September 2023 and since this time DRd has become the standard of care regimen for TIE patients with newly diagnosed multiple myeloma in the UK. Although there are reports of real world experience (RWE) of DRd efficacy in relapsed setting, there are no RWE reports of DRd efficacy and outcomes from the UK where it is used in the upfront setting and very limited data from Europe. Moreover, UK clinicians often adopt a pragmatic dose adjustment approach, particularly in the dosing of lenalidomide (escalation and de-escalation) with steroid tapering. As well as reducing short-term toxicities, this approach may lead to longer term benefits by reducing long-term steroid adverse effects such as steroid-induced diabetes, help ameliorate immune paresis and reduce infection risk.

However, there is very limited data on the efficacy and outcomes of this practice. In particular, there is no published RWE on the impact of pre-emptive dose modifications on tolerability and efficacy in frail patients, the cohort in which the highest treatment discontinuation rates were observed in the MAIA trial. It is also perceived that patients with comorbidities, which would have been excluded in MAIA cohort, are benefiting from this flexible approach in real world practice, especially people with chronic kidney disease and other comorbidities. A proportion of patients initially deemed fit for autologous stem cell transplantation (received D-VTD as induction) are also receiving DRd if they fail to receive a transplant. These patients were not represented in the MAIA study and the outcomes following de-escalation from D-VTD to DRd are unknown.

03

Conditions studied

  • Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Sites participating in this study will be those who have prescribed DRd for newly diagnosed transplant ineligible patients since this triple combination was reimbursed for use in the UK healthcare system in 2023.

Within the study, data will be collected from the medical records of adult patients aged ≥18 years with ND MM, who are ineligible for transplant and who have received at least one dose of DRd outside of clinical trials.

To be eligible for inclusion in the study, the date of the first dose should be:

  • on or before 31 December 2024, between September 2023 to 31 December 2024 (first data cut)
  • on or before 31 December 2025, between September 2023 and 31 December 2025 (second data cut)

Data will be analysed in Q1 2026 to assess treatment outcomes at 12 months (to 31 December 2025) and in Q1 2027 to assessment 12- and 24-months treatment outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of NDMM
  • Not eligible for stem cell transplant at diagnosis
  • Received frontline DRd treatment following NICE approval (post-September 2023)
  • Minimum 3 months of follow-up data available

Exclusion criteria

Exclusion Criteria:

  • Participation in an interventional clinical trial for therapy
  • Insufficient treatment or follow-up data for analysis
  • DRd used in setting rather than newly diagnosed disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
300 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall response rate (OOR) at 12 months

    Proportion with partial response (PR) or better (per IMWG criteria).

    Time frame: 12 months

  2. Real-world dosing strategy for DRd - starting doses of Daratumumab, Lenalidomide and dexamethasone in cycle 1 and relative dose intensity at 12 months

    % of patients who have had a dose adjustment in any of the DRD treatment components within the first 12 months of treatment

    Time frame: 12 months

Secondary outcomes

  1. Progression -Free Survival (PFS) at 12 and 24 months

    Time from first dose to documented disease progression or death (whichever first) Median time to disease progression or death

    Time frame: 12 months and 24 months

  2. Overall survival at 12 and 24 months

    Time from first dose to death from any cause

    Time frame: 12 months and 24 months

  3. Very good partial response (VGPR)

    Per IMWG response definitions (CR = negative immunofixation in serum \& urine + \<5% bone-marrow plasma cells; sCR adds normal free light-chain ratio and absence of clonal plasma cells).

    Time frame: 24 months

  4. Occurrence of severe infections

    % of patients who have had a grade 3 or 4 infection within 12 or 24 months of starting treatment

    Time frame: 12 months and 24 months from starting treatment

  5. Treatment exposure /discontinuation (Treatment deliverability)

    Median duration of treatment % treatment discontinuation before 12 and 24 months

    Time frame: 12 months and 24 months

  6. Dosing practice and outcome difference between academic and DGH trusts

    Time frame: 12 months and 24 months

  7. Treatment setting

    Proportion of patients receiving daratumumab in the community via an outreach service

    Time frame: 12 months and 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jul 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07532473
Lead sponsor
The Royal Wolverhampton Hospitals NHS Trust
Collaborators
Johnson & Johnson
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Tanweer Ahmed
Contact
rwh-tr.ukchart@nhs.net
01902 695065
Hannah Giles
principal investigator · University Hospital Birmingham NHS Foundation Trust

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion